Welcome to
Understanding CAR T-cell Therapy as a Treatment Option for Blood Cancer Patients
June 28, 2019
Rockefeller University
Caspary Auditorium , New York, NY , 10065
Program: 8:00 am - 4:30 pm
Learning Objectives At the conclusion of this activity, participants will be able to:
• Explain the emerging role of chimeric antigen receptor (CAR) T-cell treatment as an option for patients with relapsed/refractory blood cancer• Discuss treatment plans for patient care• Explain potential short- and long-term side effects and management• Identify patients who could potentially be treated with CAR therapy• Engage patients and caregivers in discussions on CAR T-cell therapies including benefits, risks, and barriers to entryTarget Audience Hematologists-oncologists, medical oncologists, oncology fellows, pharmacists, physician assistants, nurse practitioners, nurses, and oncology social workers at the intermediate and advanced level involved in the care of patients with hematologic malignancies.
Questions/GrievancesFor questions, grievances, or assistance with special needs (physical, dietary, etc.) please contact us prior to the program at (914) 821-8420 or email caroline.kornhauser@lls.org.Providers This activity is jointly provided by The Leukemia & Lymphoma Society & Medical Learning Institute, Inc.
Supporters This activity is supported by educational grants from Celgene Corporation, and Kite, a Gilead Company.
Continuing Education Information (See additional Tab) There is no fee for this educational activity. To receive credit for this CME/CPE/CE activity, complete the preassessment, course, post- assessment, and evaluation and return it to the on-site coordinator. Your certificate of credit will be e-mailed to you within 4 weeks. For pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: mycpemonitor.net.